Media Articles Related to Dibenzyline (Phenoxybenzamine)
For diagnosis of rare adrenal tumors, experts recommend blood, urine testing
Source: Headache / Migraine News From Medical News Today [2014.06.05]
The Endocrine Society has issued a Clinical Practice Guideline (CPG) for the diagnosis and treatment of two types of rare adrenal tumors - pheochromocytomas and paragangliomas - that can raise the...
Published Studies Related to Dibenzyline (Phenoxybenzamine)
Alpha-adrenoreceptor blockade with phenoxybenzamine does not affect the ability of the nose to condition air. [2005.07]
The primary function of the nose is to warm and humidify air. We have previously shown that raising nasal mucosal temperature by immersing feet in warm water increases the amount of water evaporated by the nose as air passes through it (nasal conditioning capacity; Abbott D, Baroody F, Naureckas E, and Naclerio R...
[Prevention and release of epidural-morphine-induced urinary retention with phenoxybenzamine and neostigmine] [2000.12]
OBJECTIVE: To study the effects of preoperative phenoxybenzamine (o.p) on preventing epidural-morphine-induced urinary retention and effects of neostigmine on releasing it... CONCLUSION: Preoperative phenoxybenzamine can not prevent epidural-morphine-induced urinary retention. Neostigmine can release the urinary retention only when preoperative phenoxybenzamine is used.
Treatment of impotence by intrapenile injections of papaverine and phenoxybenzamine: a double blind, controlled trial. [1989.04]
The efficacy of papaverine and phenoxybenzamine as a pharmacological treatment of impotence was compared in a double blind, crossover, placebo controlled trial.Sexual function during the month after injection was better with either drug when compared with placebo.
Evaluation of phenoxybenzamine in the CFA model of pain following gene expression studies and connectivity mapping. [2010.09.16]
CONCLUSION: Evaluation of phenoxybenzamine-induced analgesia in the current study lends support to the utility of the Connectivity Map approach for identifying compounds with analgesic properties in the CFA model.
Predictive factors and the effect of phenoxybenzamine on outcome in dogs undergoing adrenalectomy for pheochromocytoma. [2008.11]
BACKGROUND: Some studies in dogs undergoing adrenalectomy for pheochromocytoma suggest that anesthetic complications and perioperative mortality are common. In humans, surgical outcome has improved with the use of phenoxybenzamine (PBZ) before adrenalectomy... CONCLUSIONS AND CLINICAL IMPORTANCE: Results from this retrospective study support treatment with PBZ before surgical removal of pheochromocytoma in dogs.
Clinical Trials Related to Dibenzyline (Phenoxybenzamine)
Intravenous Phenoxybenzamine Use in Pediatric Patients Undergoing Open-Heart Surgery [Recruiting]
Cardiopulmonary bypass is done with a machine that does the work of the heart and lungs
during open-heart surgery. This study is to determine if intravenous (i. v.)
phenoxybenzamine is safe. This drug lowers the blood pressure, making it easier for the
cardiopulmonary bypass machine to deliver blood and oxygen to all of the organs and tissues.
Use of Phenoxybenzamine [PBZ] IV to Assist High Flow Low Pressure Perfusion [HFLPP] on Cardio-Pulmonary Bypass [Recruiting]
Cardiopulmonary bypass [CPB] in small size bodies can result in decreased peripheral
perfusion. This results in anaerobic metabolism as evidenced by lactic acidosis. High flow
perfusion results in systemic hypertension which is accentuated by moderate hypothermia
commonly used during cardiopulmonary bypass. Phenoxybenzamine [PBZ] is an arteriolar
vasodilator that acts by irreversibly blocking the alpha adrenergic receptors. It causes
vasodilatation allowing high flow, low pressure CPB. It has been used extensively outside US
in Canada, Europe and Australia. In the US oral PBZ is FDA approved, whereas intravenous PBZ
is only available as an investigational drug
Phenoxybenzamine Versus Doxazosin in PCC Patients [Recruiting]
- Rationale: The optimal preoperative medical management for patients with a
pheochromocytoma is currently unknown. In particular, there is no agreement with
respect to whether phenoxybenzamine or doxazosin is the optimal alfa-adrenoreceptor
antagonist to be administered before surgical resection of a pheochromocytoma. We
hypothesized that the competitive alfa1-antagonist doxazosin is superior to the
non-competitive alfa1- and alfa2-antagonist phenoxybenzamine.
- Objective: comparing effects of preoperative treatment with either phenoxybenzamine or
doxazosin on intraoperative hemodynamic control in patients undergoing surgical
resection of a pheochromocytoma.
- Study design: Randomised controlled open-label trial.
- Study population: 18 - 55 yr old. Adult patients with a recently diagnosed benign
- Intervention: Patients are randomised to receive oral treatment with either
phenoxybenzamine or doxazosin preoperatively.
- Main study parameters/endpoints: The main study parameter is defined as the frequency
of intraoperative blood pressure episodes outside the predefined target range after
pretreatment with either phenoxybenzamine or doxazosin.
In this multicenter trial, we compare the effects of two commonly used drugs in patients
being medically prepared for resection of a benign pheochromocytoma. Participants are not
subjected to an experimental treatment of any kind, as we merely aim to describe in detail
the perioperative course in general and, in particular, the intraoperative hemodynamic
control in patients treated preoperatively with either phenoxybenzamine or doxazosin. A
routine diagnostic work-up for pheochromocytoma will be performed in all participants. One
extra blood sample (volume: 48,5 mL) is drawn before start of the study medication, and
participants need to record their symptoms in a diary. In addition, patients who are
pretreated in the outpatient clinic monitor their blood pressure and pulse rate at home with
an automated device. Treatment with an alfa-adrenoreceptor antagonist is initiated at least
2 - 3 weeks prior to surgery. Patients who are admitted to the hospital for pretreatment
with an alfa-adrenoreceptor antagonist have their blood pressure and pulse rate measured by
the nursing staff. The final site visit is planned at 30 days after surgery, in line with
Parenteral Phenoxybenzamine During Congenital Heart Disease Surgery [Not yet recruiting]
Phenoxybenzamine, an irreversible alpha-adrenergic blocker, may prove beneficial to infants
and children with congenital heart disease undergoing open cardiac repair, due to a
theoretic benefits of a uniform and smooth reduction in systemic vascular resistance in the
perioperative period. Vasodilation allows for low pressure, high flow systemic perfusion
while on cardiopulmonary bypass. Support for the use of phenoxybenzamine in humans has been
documented in several studies involving the perioperative management of both adults and
children requiring cardiopulmonary bypass, and in management of patients with
pheochromocytoma. 1-7 Phenoxybenzamine has been associated with more uniform body cooling
and rewarming, and improved tissue perfusion during bypass. 8 It is also known to increase
cardiac output, stroke volume, and renal blood flow when given intravenously. 9 Specifically
in pediatric open heart surgery, the combined use of phenoxybenzamine and dopamine provided
a stable hemodynamic condition without a high total peripheral vascular resistance and
stimulated postoperative diuresis. 9 Afterload reduction with parenteral phenoxybenzamine in
neonates undergoing the Norwood procedure for hypoplastic left heart syndrome is associated
with improved systemic oxygen delivery and stabilization of systemic vascular resistance. 10
Furthermore, a strategy of reducing afterload with phenoxybenzamine and stabilizing the
pulmonary to systemic flow ratio in this select population of patients has also been shown
to improve operative survival. 11 We hypothesize that phenoxybenzamine will reduce
afterload on the systemic ventricle in our selected patient population, thereby improving
ventricular performance and decreasing the risks of pulmonary to systemic flow imbalance
associated with current short-acting vasodilator therapy. We will plan to evaluate both
physiologic variables as well as surgical outcomes in the selected study population.